AGA calls on FDA to Retain Access to Conventional FMT
In addition to the new FDA-approved therapies, we still need access to conventional fecal microbiota transplantation for complicated and vulnerable patients with C. diff infection.
In addition to the new FDA-approved therapies, we still need access to conventional fecal microbiota transplantation for complicated and vulnerable patients with C. diff infection.